Production report for April 2023
Oslo,22May 2023
| March2023 | April2023 | |||
| Operated | Boepd (1) | Bopd (2) | Boepd (1) | Bopd (2) |
| Colombia | 665 | 443 | 745 | 525 |
| Argentina | 1,942 | 277 | 1,591 | 194 |
| Total operated | 2,607 | 720 | 2,336 | 719 |
| Total equity | 577 | 308 | 601 | 352 |
(1) Barrels of oil equivalents per day (includes liquid and gas)
(2) Barrels of oil per day (represents only liquids)
[boepd]: barrels of oil equivalents per day (includes liquid and gas)
[Operated]: 100% field production operated by Interoil
[Equity] : Interoil’s share production net of royalties.
Comments
In March 2023, unfortunately Interoil’s average daily operated production decreased by 271 boepd where most of the lost production is related with operational issues in Argentina where the austral winter arrived sooner than expected. Fortunately, Colombia community distress situation was solved, and operations are slowly recovering to its previous figures.
In Argentina, production losses averaged some 350 boepd, mostly from the Santa Cruz fields, due to mild winter temperatures and strong winds causing most of the lost production. Interoil is working hard in solving significant surface production issues related with some obstruction in most of the hydrocarbon pipe network system connecting different gas fields among themselves.
In Colombia, Puli C production experience a slightly increase of 80 boepd as operation was slowly re-established after the community restrictions experience along April. Fortunately, production gradually resume alongside the oil trucking sale. In the Llanos area, Vikingo production flows remained stable following at its natural depletion rate. The exploration campaign in Altair and LLA-47 blocks remains on hold pending approval from local authorities. Conversations with the ANH concerning the formal approval is still on hold waiting for the new authorities to take position.
Additional information
Further details about production performance are shown in the document attached. The two graphs and tables show operated and equity production of oil and gas respectively and by country. Operated production is defined as total output from fields operated by Interoil. Equity production is Interoil’s share of production net of royalties.
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
***************************
Please direct any further questions to ir@interoil.no
Interoil Exploration and Production ASA is a Norwegian based exploration and production company - listed on the Oslo Stock Exchange with focus on Latin America. The Company is operator and license holder of several production and exploration assets in Colombia and Argentina with headquarter in Oslo.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
ING announces share buyback programme of up to €2.5 billion2.5.2024 07:03:00 CEST | Press release
ING announces share buyback programme of up to €2.5 billion ING announced today a share buyback programme under which it plans to repurchase ordinary shares of ING Groep N.V., for a maximum total amount of €2.5 billion. The purpose of the share buyback programme is to converge our CET1 ratio towards our target of around 12.5%. ING Group’s CET1 ratio was 14.8% at the end of the first quarter of 2024, which is well above the prevailing CET1 ratio requirement of 10.94%. The share buyback programme will have an impact of approximately 77 bps on our CET1 ratio. The programme will commence on 2 May 2024 and is expected to end no later than 29 October 2024. The ECB has approved the programme, which will be executed in compliance with the Market Abuse Regulation and within the limitations of the existing authority to acquire a maximum of 20% of the issued shares as granted by the general meeting of shareholders on 22 April 2024. ING has entered a non-discretionary arrangement with a financial
CEX.IO Launches Mastercard-branded Crypto Debit Card2.5.2024 07:00:00 CEST | Press release
The new product enables registered users in the EEA to make everyday payments with their crypto holdings, and integrates seamlessly with CEX.IO App. VILNIUS, May 02, 2024 (GLOBE NEWSWIRE) -- CEX.IO, a global ecosystem working to bridge the worlds of crypto and traditional finance, announces the debut of CEX.IO Card, a debit card that empowers users to seamlessly spend their crypto assets on everyday purchases. This innovative product marks a pivotal step forward in CEX.IO’s mission to simplify crypto adoption, and bring the benefits of decentralized finance to the masses. The CEX.IO Card seamlessly integrates into users’ existing spending habits, allowing them to effortlessly make purchases with millions of merchants who accept Mastercard, in over 150 countries. Users can fund their cards via a variety of accessible methods, including bank transfers, as well as fiat and crypto deposits. In addition, they may set ranked priorities for their preferred methods, ensuring they always have a
ONWARD® Medical Convocation of the 2024 Annual General Meeting of Shareholders and Proposed Resolutions2.5.2024 07:00:00 CEST | Press release
EINDHOVEN, the Netherlands, May 02, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today has convened the 2024 Annual General Meeting of Shareholders (AGM), which will include consideration of the resolutions to be submitted for adoption at the AGM, which will be held in Amsterdam, the Netherlands, on June 13, 2024. The resolutions, proposed by the Board, to be submitted for adoption at the AGM, are as follows: Adoption of the Company’s statutory annual accounts for the financial year ended December 31, 2023, prepared in accordance with International Financial Reporting Standards (IFRS-EU). The 2023 statutory accounts were filed with the Netherlands Authority for the Financial Markets (AFM) on April 25, 2024, and are posted on the Company’s website (www.ir.onwd.com) and the AFM's website (afm.nl). Imp
Biotalys Starts Field Trials for Second Biofungicide2.5.2024 07:00:00 CEST | Press release
Ghent, BELGIUM, May 02, 2024 (GLOBE NEWSWIRE) -- Biotalys (Euronext: BTLS) an Agricultural Technology (AgTech) company developing protein-based biocontrols for sustainable crop protection, today announced the initiation of field trials for BioFun-6, the company’s second biofungicide program under development on its AGROBODY technology platform. Kevin Helash, Chief Executive Officer of Biotalys,commented: “Moving BioFun-6 into the field is another important milestone for Biotalys, demonstrating our ability to advance a series of protein-based bioactive ingredients on our platform in concert. As our first product candidate, EVOCA™, progresses through the needed regulatory process and its commercial version EVOCA NG enters its final development stage with our partner Novonesis, we will continue to build our strong pipeline of biofungicides and bioinsecticides to help growers in their transition towards more sustainable practices.” BioFun-6 is a biofungicide targeting botrytis, powdery mil
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations2.5.2024 07:00:00 CEST | Press release
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the outcomes from HARMONIE, a phase 3b clinical study conducted in close to real-life conditions7-10 Paris, May 2, 2024. Beyfortus reduced respiratory syncytial virus (RSV) hospitalizations by 82% (95% CI: 65.6 to 90.2) in infants under 6 months of age, compared to infants who received no RSV intervention, according to the interim results of an ongoing study published in The Lancet. These results, from the first RSV season after Beyfortus’ introduction, are part of the three-year NIRSE-GAL study conducted in Galicia, Spain un